Novartis Lifts Earnings Guidance as Q3 Sales and Profit Grow
Novartis reported Q3 net sales up 4% to $14.5 billion and core operating income up 11% to $6 billion. Core operating margin rose to 41.6%, and core EPS climbed 9% to $2.46. Growth was led by breast cancer treatment sales.
The Swiss pharmaceutical group said net sales rose 4% to $14.5bn in the three months to 30 September, while core operating income increased 11% to $6bn, helped by a 2.3pp increase in the core operating margin to 41.6%. Core earnings per share climbed 9% to $2.46.Growth was led by breast cancer trea…